Pancreatic Cancer Research

ResearcherUniversity of InsubriaActive in the last 2 years

Gianpaolo Balzano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4636-4566; OpenAlex author ID A5033134171. Sources: ClinicalTrials.gov.

Their work

Papers
50 (first author 3, last author 3)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
171
Papers, trials and grants by year

2012: 3 papers · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 8 papers · 2017: 3 papers · 2018: 6 papers, 1 trial · 2019: 3 papers · 2020: 5 papers · 2021: 3 papers · 2022: 4 papers · 2023: 4 papers · 2024: 3 papers · 2025: 2 papers · 2026: 4 papers

Papers 50

  1. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
  2. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  3. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the … Co-author DOI 10.1016/s0140-6736(25)01685-x↗
  4. Upfront Chemotherapy Versus Immediate Surgery for Operable Pancreatic Cancer: An Umbrella Review of Meta-Analyses. Co-author DOI 10.3390/cancers18091344↗
  5. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  6. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  7. Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ctro.2024.100778↗
  8. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  9. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  10. Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples. Co-author DOI 10.1016/j.cgh.2022.10.014↗
  11. Pro-tumor Tfh2 cells induce detrimental IgG4 production and PGE2-dependent IgE inhibition in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2023.104819↗
  12. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  13. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  14. Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC). Co-author DOI 10.1245/s10434-022-11413-7↗
  15. Needle-Tract Seeding of Pancreatic Cancer after EUS-FNA: A Systematic Review of Case Reports and Discussion of Management. Co-author DOI 10.3390/cancers14246130↗
  16. A Comprehensive Characterization of Stemness in Cell Lines and Primary Cells of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms231810663↗
  17. EUS-guided ablation with the HybridTherm Probe as second-line treatment in patients with locally advanced pancreatic ductal adenocarcinoma: A case-control stud… Co-author DOI 10.4103/eus-d-21-00200↗
  18. Resectability of Pancreatic Cancer Is in the Eye of the Observer: A Multicenter, Blinded, Prospective Assessment of Interobserver Agreement on NCCN Resectabili… Last author DOI 10.1097/as9.0000000000000087↗
  19. Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies. Last author DOI 10.3389/fonc.2021.812102↗
  20. Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectable Pancreatic Cancer: A Phase II Randomi… Co-author DOI 10.3390/cancers13184512↗
  21. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  22. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-020-04047-7↗
  23. Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic can… Co-author DOI 10.1016/j.ejso.2020.02.013↗
  24. Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer": What Is Good for the Surgeo… Co-author DOI 10.1097/sla.0000000000003655↗
  25. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Sco… Co-author DOI 10.1245/s10434-019-08137-6↗
  26. Corrigendum to "Evolution of pancreatectomy with en bloc venous resection for pancreatic cancer in Italy. Retrospective cohort study on 425 cases in 10 pancrea… Co-author DOI 10.1016/j.ijsu.2019.05.015↗
  27. The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreati… Co-author DOI 10.1186/s40425-019-0521-4↗
  28. Postoperative Outcomes and Functional Recovery After Preoperative Combination Chemotherapy for Pancreatic Cancer: A Propensity Score-Matched Study. Last author DOI 10.3389/fonc.2019.01299↗
  29. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreati… Co-author DOI 10.1016/j.ejca.2018.07.007↗
  30. Evolution of pancreatectomy with en bloc venous resection for pancreatic cancer in Italy. Retrospective cohort study on 425 cases in 10 pancreatic referral uni… Co-author DOI 10.1016/j.ijsu.2018.05.025↗
  31. Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected pancreatic cancer: A correlation with c… Co-author DOI 10.1016/j.pan.2018.09.006↗
  32. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. First author DOI 10.1016/s2468-1253(18)30081-5↗
  33. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. Co-author DOI 10.1016/s2468-1253(18)30196-1↗
  34. No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. Co-author DOI 10.3233/cbm-181218↗
  35. A preoperative score to predict early death after pancreatic cancer resection. Co-author DOI 10.1016/j.dld.2017.06.012↗
  36. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Co-author DOI 10.1093/annonc/mdx495↗
  37. Modeling the Iatrogenic Pancreatic Cancer Risk After Islet Autotransplantation in Mouse. Co-author DOI 10.1111/ajt.14360↗
  38. Effect of sarcopenia and visceral obesity on mortality and pancreatic fistula following pancreatic cancer surgery. Co-author DOI 10.1002/bjs.10063↗
  39. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Co-author DOI 10.1016/j.ejso.2016.06.398↗
  40. Overuse of surgery in patients with pancreatic cancer. A nationwide analysis in Italy. Co-author DOI 10.1016/j.hpb.2015.11.005↗
  41. Diabetes associated with pancreatic ductal adenocarcinoma is just diabetes: Results of a prospective observational study in surgical patients. Co-author DOI 10.1016/j.pan.2016.08.005↗
  42. Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic… First author DOI 10.1038/bjc.2016.209↗
  43. Basophil Recruitment into Tumor-Draining Lymph Nodes Correlates with Th2 Inflammation and Reduced Survival in Pancreatic Cancer Patients. Co-author DOI 10.1158/0008-5472.can-15-1801-t↗
  44. (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial. Co-author DOI 10.1158/1078-0432.ccr-15-1722↗
  45. Effect of Diabetes on Survival after Resection of Pancreatic Adenocarcinoma. A Prospective, Observational Study. Co-author DOI 10.1371/journal.pone.0166008↗
  46. Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer. Co-author DOI 10.1007/s13277-014-2716-0↗
  47. Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a pha… Co-author DOI 10.1016/j.ijrobp.2013.09.012↗
  48. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirub… Co-author DOI 10.1007/s00280-011-1680-2↗
  49. Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer. Co-author DOI 10.1016/j.gie.2012.08.006↗
  50. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. First author DOI 10.1245/s10434-011-2205-2↗

Trials 1

  1. Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer Principal investigator NCT03673423↗

Closest collaborators

The 25 strongest of 171 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Massimo Falconi · 33 shared papers, 2016–2026 · strength 3.42
  2. Michele Reni · 29 shared papers, 2012–2026 · strength 2.61
  3. Claudio Doglioni · 20 shared papers, 2012–2023 · strength 1.62
  4. Paolo Giorgio Arcidiacono · 11 shared papers, 2012–2023 · strength 1.07
  5. Giulio Belfiori · 7 shared papers, 2017–2026 · strength 0.99
  6. Stefano Crippa · 8 shared papers, 2016–2026 · strength 0.85
  7. Domenico Tamburrino · 5 shared papers, 2019–2026 · strength 0.79
  8. Marina Macchini · 6 shared papers, 2018–2026 · strength 0.77
  9. Marco Schiavo Lena · 5 shared papers, 2020–2026 · strength 0.74
  10. Nicolò Pecorelli · 5 shared papers, 2016–2026 · strength 0.65
  11. Giulia Orsi · 4 shared papers, 2020–2026 · strength 0.64
  12. Giuseppe Malleo · 5 shared papers, 2020–2026 · strength 0.62
  13. Valentina Pasquale · 8 shared papers, 2016–2022 · strength 0.58
  14. Erica Dugnani · 8 shared papers, 2016–2022 · strength 0.58
  15. Lorenzo Piemonti · 8 shared papers, 2016–2022 · strength 0.58
  16. Maria Chiara Petrone · 5 shared papers, 2012–2023 · strength 0.58
  17. Stefano Partelli · 5 shared papers, 2016–2026 · strength 0.51
  18. Diego Palumbo · 3 shared papers, 2021–2026 · strength 0.51
  19. Francesco DE COBELLI · 4 shared papers, 2016–2026 · strength 0.50
  20. Silvia Matilde Zanon · 7 shared papers, 2016–2020 · strength 0.47
  21. Ugo Boggi · 5 shared papers, 2018–2024 · strength 0.46
  22. Roberto Salvia · 4 shared papers, 2020–2025 · strength 0.45
  23. Tobias Keck · 4 shared papers, 2020–2025 · strength 0.44
  24. Adnan A. Alseidi · 4 shared papers, 2020–2025 · strength 0.44
  25. Giovanni Butturini · 4 shared papers, 2020–2025 · strength 0.44

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.